A Randomized Phase II study of S-1 and LV versus S-1, LV and L-OHP versus S-1 and CDDP in Patients with Advanced Gastric Cancer
Phase 2
- Conditions
- Gastric Cancer
- Registration Number
- JPRN-jRCT2080221595
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 144
Inclusion Criteria
Patients must be diagnosed as advanced gastric cancer
- Age: 20 years or order
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Sufficient oral intake
- Written informed consent
- At least one measurable lesion by RECIST criteria
Exclusion Criteria
- Diarrhea
- History or presence of severe pulmonary disease
- History or presence of severe heart disease
- Uncontrolled or severe diabetes
- Severe complications(e.g., severe enteritis, severe stomatitis, gastrointestinal ulcer)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method